Detailed price information for Iovance Biotherapeutics Inc (IOVA-Q) from The Globe and Mail including charting and trades.

Mabel Mardones, MD, Rocky Mountain Cancer Centers, discusses the future of HR+/HER2– breast cancer treatment, focusing on the importance of biomarkers and the potential of SIRDs to improve patient ...

Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing in immunotherapy for ...

Wayne Pisano, Chair of Oncolytics’ board and interim CEO, stated, “With positive BRACELET-1 results, we have two randomized phase two studies confirming pelareorep’s potential in HR+/HER2- metastatic ...

The Pixel 9 Pro caught our eyes with its compact nature, flagship cameras and a premium design. Does it make for the ideal ...

Today announced third quarter financial results and operational highlights. Highlights include BRACELET-1 data showing impressive overall survival benefit in HR+/HER2- metastatic breast cancer affirms ...

A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling ...

“Onco360 is grateful for the opportunity to partner with the team at Genentech and become a specialty pharmacy provider for ItovebiTM,” said Benito Fernandez.“We are proud to add another treatment ...

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, announces new positive survival data, ...

Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, ...

Notably, Trodelvy is the standard of care for second-line metastatic triple-negative breast cancer, with ongoing adoption in the pretreated HR+/HER2- metastatic breast cancer setting. We're pleased to ...